Rhythm Pharmaceuticals (RYTM) Cash & Equivalents (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash & Equivalents data on file, last reported at $62.1 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 41.43% year-over-year to $62.1 million in Q1 2026; TTM through Mar 2026 was $62.1 million, a 41.43% decrease from a year earlier, with the FY2025 full-year figure at $54.3 million, down 39.08% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $62.1 million, up from $54.3 million in the prior quarter.
• Over the last five years, Cash & Equivalents for RYTM reached as high as $416.1 million in Q3 2025 and fell as low as $48.0 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $116.8 million across 5 years, with a median of $106.1 million in 2025.
• Across the five-year window, Cash & Equivalents plunged 64.99% in 2023 and surged 767.18% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $128.0 million in 2022, then plunged by 52.81% to $60.4 million in 2023, then soared by 47.56% to $89.1 million in 2024, then plunged by 39.08% to $54.3 million in 2025, then gained by 14.43% to $62.1 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $62.1 million in Q1 2026, $54.3 million in Q4 2025, and $416.1 million in Q3 2025.